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LSD1 is a critical chromatin modulator that controls
cellular pluripotency and differentiation through the
demethylation of H3K4me1/2. Overexpression of
LSD1 has been observed in many types of tumors
and is correlated with its oncogenic effects in tumor-
igenesis. However, the mechanism leading to LSD1
upregulation in tumors remains unclear. Using an
unbiased siRNA screening against all the human
deubiquitinases, we identified USP28 as a bona
fide deubiquitinase of LSD1. USP28 interacted with
and stabilized LSD1 via deubiquitination. USP28
overexpression correlated with LSD1 upregulation
in multiple cancer cell lines and breast tumor
samples. Knockdown of USP28 resulted in LSD1
destabilization, leading to the suppression of cancer
stem cell (CSC)-like characteristics in vitro and
inhibition of tumorigenicity in vivo, which can be
rescued by ectopic LSD1 expression. Our study
reveals a critical mechanism underlying the epige-
netic regulation by USP28 and provides another
treatment approach against breast cancer.
INTRODUCTION
Posttranslational modifications, such as phosphorylation, acety-
lation, and methylation, of histone tails are crucial epigenetic
marks that regulate diverse cellular processes. Methylation, in
particular, has a global effect on cell-cycle control, tumor
progression, and embryonic stem cell (ESC) self-renewal and
differentiation (Klose and Zhang, 2007). The best characterized
modifications are themethylation of the Lys9 and Lys27 residues
of histone H3 (H3K9me2/3 and H3K27me3), which associates224 Cell Reports 5, 224–236, October 17, 2013 ª2013 The Authorswith heterochromatin and generally represses transcription,
and H3K4me2/3, which often associates with actively tran-
scribed gene promoters. These epigenetic modifications create
unique promoter architectures that control gene expression.
Lysine methylation is a dynamic and reversible process.
Lysine-specific demethylase 1 (LSD1) was the first discovered
histone demethylase that specifically removes H3K4me1/2
through flavin-adenine-dinucleotide (FAD)-dependent oxidative
reaction (Shi et al., 2004). LSD1 is also involved in the demethy-
lation of H3K9 when associated with androgen receptor
(Metzger et al., 2005). LSD1 exhibits its functions in gene repres-
sion by operating as a key component of several corepressor
complexes, such as Co-REST, NuRD, CtBP, HDAC, or Sirt1
(Mulligan et al., 2011; Nicholson and Chen, 2009). Genetic abla-
tion of LSD1 in mice causes embryonic lethality, and LSD1-defi-
cient ESCs have cell defects and global DNA hypomethylation
(Wang et al., 2007, 2009), suggesting that LSD1 is required for
the maintenance and differentiation of stem cells. In addition,
LSD1 and several master transcriptional factors of ESC, such
as Oct4, Sox2, and Nanog, co-occupy the high-confidence pro-
moter and enhancer regions of a subset of key developmental
genes during early embryonic development to control the bal-
ance between self-renewal and differentiation (Foster et al.,
2010; Whyte et al., 2012). Interestingly, aberrant elevation of
LSD1 has been observed in poorly differentiated neuroblastoma,
sarcoma, and neuroendocrine carcinomas (Bennani-Baiti et al.,
2012; Magerl et al., 2010; Schulte et al., 2009). LSD1 is also over-
expressed in breast, bladder, lung, and colon cancers (Hayami
et al., 2011; Lim et al., 2010). Despite the fact that LSD1 is an
important determinant of stem cell pluripotency and differentia-
tion and its critical role in tumorigenesis, the mechanism leading
to the aberrant upregulation of LSD1 in tumor remains unclear.
Protein abundance is tightly regulated by transcriptional and
posttranscriptional mechanisms. Previous studies have sug-
gested that LSD1 is an unstable protein and subjected to protea-
some degradation (Lin et al., 2010; Shi et al., 2005). Although
ubiquitination plays a central role in controlling the rapid turnover
of many key molecules to regulate a diverse array of cellular pro-
cesses (Cardozo and Pagano, 2004), deubiquitination, the
reverse process that mediates by deubiquitinases (DUBs), has
gained increasing appreciation as an important mechanism in
controlling protein turnover (Reyes-Turcu et al., 2009; Sowa
et al., 2009). DUBs are emerging as important modulators of
carcinogenesis by controlling several key signaling pathways.
For example, CYLD is a key DUB for removing the ubiquitination
of several key components of NF-kB signaling pathway,
including TRAF2/6 and NEMO. Loss of CYLD activity allows pro-
longed NF-kB activation and neoplasm transformation (Brum-
melkamp et al., 2003).
To better understand the mechanism underlying the upregula-
tion of LSD1 in cancer, we undertook the unbiased approach of
screening an siRNA library of DUBs to identify the specific DUBs
of LSD1. We found that USP28 is a bona fide DUB of LSD1 and
plays a critical role in breast cancer.
RESULTS
USP28 Stabilizes LSD1 at the Protein Level
Previous studies suggested that LSD1 was subjected to protea-
some degradation (Lin et al., 2010; Shi et al., 2005). To extend
this observation, we expressed Flag-LSD1 in HEK293 cells fol-
lowed by treatment with several proteasome inhibitors, including
MG132, lactacystin, bortezomib, or carfilzomib, for 6 hr. LSD1
became significantly stabilized by about 5-fold after the treat-
ment with these pharmacological inhibitors that have different
modes of action in suppressing proteasome-mediated protein
degradation (Figure 1A). We treated breast cancer (MDA-
MB157), pancreatic cancer (Capan-1), and colon cancer
(DLD1) cells with MG132 and noticed that the level of endoge-
nous LSD1 was also stabilized by MG132 (Figure 1B). Protein
ubiquitination is a dynamic process, involving enzymes that
add ubiquitin (ubiquitin ligases) and enzymes that remove ubiq-
uitin (DUBs). To identify the potential DUB of LSD1, we screened
cells with a siRNA library that consists of four nonoverlapping
siRNAs targeting 99 known or putative DUBs (data not shown).
This initial screen identified 24 genes that may directly or indi-
rectly control LSD1 stability. When these DUBs were coex-
pressed with LSD1 in HEK293 cells, we noticed that USP28
significantly increased LSD1 level, similar to that treated with
MG132 (Figure S1A). However, expression of a mutant USP28,
in which the catalytic cysteine has been replaced by alanine
(C171A), failed to stabilize LSD1 (lane 3, Figure 1C). In addition,
USP25, a DUB thatmost closely related to USP28, could not sta-
bilize LSD1 (lane 4, Figure 1C). The steady-state level of LSD1
was enhanced by ectopic USP28 expression in a dose-depen-
dent manner (Figure 1D). Conversely, knockdown of endoge-
nous USP28 resulted in a drastic decrease of endogenous
LSD1 protein but not mRNA in breast (BT549 and MCF7) and
colon (HCT116 and HT29) cancer cells (Figure 1E). This observa-
tion was further confirmed with immunofluorescent analysis
showing that the loss of LSD1 staining colocalized with USP28
knockdown in nuclei (Figure 1F). Interestingly, the downregula-
tion of LSD1 by two independent USP28 small hairpin RNAs
(shRNAs) in HCT116 cells could be restored by MG132 treat-Cment (Figure 1G), indicating that USP28 enhances LSD1 stabili-
zation through a deubiquitination event. Because LSD1 is a
major demethylase for H3K4me2, we examined the global levels
of H3K4me2 in HCT116 cells with USP28 knockdown. H3K4me2
was elevated in two cloneswith USP28 knockdown (Figure S1B).
The elevation of H3K4me2 after USP28 knockdown is likely
mediated by the downregulation of LSD1, because knockdown
of LSD1 independently also increased H3K4me2. However,
knockdown of USP28 or LSD1 did not affect the levels of
H3K9me2 and H3K27me3. Together, these data indicated that
USP28 is a specific DUB that controls the level and activity of
LSD1.
TheProtein but Not themRNALevels of USP28 andLSD1
Are Coordinately Overexpressed in Tumors
To further examine the USP28-LSD1 relationship, we analyzed
the expression of USP28 and LSD1 from two gene expression
data sets, which contain 118 and 149 breast tumor samples,
respectively (Figure S2). We did not notice any correlation in
the expression of USP28 and LSD1 at the mRNA level in these
two gene expression data sets. We also examined the mRNA
levels of USP28 and LSD1 in ten tumor cell lines and did not
found any correlation in the expression of these two molecules
at the mRNA level (top panel, Figure 2A). However, we found
that the protein levels of USP28 and LSD1 were positively corre-
lated in the majority of these tumor cell lines (except SW620)
(bottom panel, Figure 2A). In addition, we analyzed the protein
level of USP28 and LSD1 from mouse mammary gland and
from breast tumors derived from MMTV-Wnt1 and MMTV-
HER2 transgenic mice. Although we did not observe upregula-
tion of USP28 and LSD1 from mouse mammary gland and
tumors of MMTV-HER2 mice, we found an increased USP28
positively correlated with LSD1 upregulation in tumors collected
from three individual MMTV-Wnt1 transgenic mice (Figure 2B).
Furthermore, we examined the protein levels of USP28 and
LSD1 in 12 fresh-frozen breast tumor samples. Although one
sample did not match well (sample 9, Figure 2C), the majority
of these tumor samples showed a positive correlation in the
expression of USP28 and LSD1 at the protein level. The correla-
tion of USP28 and LSD1 was further validated by examining the
expression of these two molecules in 198 cases of primary
breast tumor samples using immunohistochemical staining (Fig-
ure 2D). It has been reported that USP28 expression was low and
existed in the cytoplasm in normal epithelial cells; however,
strong nuclei staining of USP28 was found in majority of tumor
cells in invasive ductal carcinomas (IDCs) (Popov et al., 2007).
Our results showed that the intensity of USP28 was positively
correlated with a strong LSD1 staining in the nucleus in these
IDC samples. Together, these results on the positive correlated
expression between USP28 and LSD1 on protein but not
mRNA level from various tumor cell lines tumor samples
strengthen our observation that USP28 is critical in controlling
the protein level of LSD1.
USP28 Interacts with LSD1
To investigate whether USP28 interacted with LSD1, we coex-
pressed Flag-LSD1 and HA-USP28 in HEK293 cells. After immu-
noprecipitating LSD1, we detected the associated USP28, andell Reports 5, 224–236, October 17, 2013 ª2013 The Authors 225
Figure 1. USP28 Stabilizes LSD1
(A) Flag-LSD1 was expressed in HEK293 cells. After treating cells with 10 mM of MG132, lactacystin, bortezomib, or carfilzomib for 6 hr, LSD1 expression was
analyzed by western blotting.
(B) Tumor cell lines were treated with 10 mM MG132 for 6 hr. Endogenous LSD1 was examined by western blotting.
(C) Flag-LSD1was coexpressedwith either Flag-tagged USP28 (wild-type or catalytic inactive C171Amutant) or USP25 in HEK293 cells. Expression of LSD1 and
USP were analyzed by western blotting.
(D) Flag-LSD1 was coexpressed with increasing amounts of Flag-USP28 in HEK293 cells. Lysates were subjected to analysis by western blotting.
(E) Tumor cell lines were transfected with control or USP28 siRNA, expression of endogenous LSD1 and USP28 was examined by western blotting. The mRNA
level of endogenous LSD1 and USP28 was also determined by real-time RT-PCR (right panel) (mean ± SD from two independent experiments with triplicate). *p
value < 0.01 when USP28 mRNA from control siRNA group was compared with that from USP28 siRNA group. #p value > 0.05 when LSD1 mRNA from control
siRNA group was compared with that from USP28 siRNA group.
(F) USP28 was knocked down by USP28 siRNA in HT29 cells. After fixation, expression of endogenous USP28 (red) and LSD1 (green) was analyzed by
immunofluorescent staining (nuclei were stained with DAPI; blue). Arrowhead points to USP28 knockdown cells. Scale bar, 10 mm.
(G) HCT116 cells stably transfected with control or two individual USP28 shRNAs were treated with 10 mMMG132 for 6 hr; expression of LSD1 and USP28 was
analyzed by western blotting.
See also Figure S1.vice versa (Figure 3A). The interaction between LSD1 and USP28
is specific, as LSD1 could not interact with USP7 and USP25
under similar conditions (Figure S3A). We also immunoprecipi-
tated endogenous LSD1 and USP28 from BT549, MCF7, and
HCT116 cells and detected the presence of endogenous
USP28 and LSD1, respectively (Figure 3B).
The N-terminal one-third of LSD1 contains a SWIRM domain
and the C-terminal two-thirds of LSD1 comprise an amine oxi-
dase (AO) domain that shares extensive sequence homology
with FAD-dependent amine oxidase (Figure 3C). To identify the
region that is responsible for the LSD1 interaction with USP28,226 Cell Reports 5, 224–236, October 17, 2013 ª2013 The Authorswe generated LSD1 domain-deletion mutants and coexpressed
them with USP28 in HEK293 cells. Immunoprecipitation of
USP28 revealed the association with full-length LSD1. A small
C-terminal deletion mutant of LSD1 and the AO domain retained
the ability to interact with USP28 (Figures 3C and S3B). The
N-terminal region of the SWIRM domain, however, was inca-
pable of interactingwith USP28. In the reciprocal immunoprecip-
itation experiment, immunoprecipitation of full-length and small
C-terminal-deleted LSD1 and the AO domain, but not the
SWIRM domain, revealed the association of USP28. These re-
sults indicate that the AO domain is required for the interaction
Figure 2. Expression of USP28 and LSD1 Are Positively Correlated at the Protein Level in Cancer Cell Lines and Breast Tumor Samples
(A) Levels of USP28 and LSD1mRNA in various tumor cell lines were analyzed by real-time RT-PCR. Values are normalized to actin (upper panel; mean ± SD from
two experiments in triplicate). Expression of endogenous USP28 and LSD1 in these tumor cell lines was analyzed by western blotting (bottom panel). Primer
sequences are listed in Table S1.
(B) Cell extracts prepared from normal mammary glands of two individual mice and from breast tumors of three individual MMTV-HER2 and MMTV-Wnt1
transgenic mice were analyzed for the expression of USP28 and LSD1 by western blotting.
(C) Expression of USP28 and LSD1 from 12 cases of fresh-frozen human breast tumors was examined by western blotting (for tumor information, see Table S2).
(D) The 198 surgical specimens of breast cancer were immunostained using antibodies against USP28, LSD1, and the control serum (data not shown).
Representative images of immunohistochemical (IHC) staining from the same tumor samples are shown in the top panel (scale bar, 50 mm), and statistical analysis
is shown in the bottom panel.
See also Figure S2 and Tables S1 and S2.of LSD1 with USP28. Consistent with this observation, when
wild-type and deletion mutants of GST-LSD1 were pulled
down from cell lysates, the SWIRM domain of LSD1 failed to
interact with USP28 (Figure 3D). To determine which region of
USP28 is responsible for the interaction with LSD1, we gener-
ated several USP28 deletion mutants and coexpressed them
with LSD1 in HEK293 cells. We found that the N-terminal region
of USP28 retained the ability to interact with LSD1 (Figures 3E
and S3C). The C-terminal region and the middle USP domain,
however, were not required for the interaction with LSD1.
Consistent with the interaction of these two molecules in vitro
and in vivo, when USP28 was coexpressed with GFP-LSD1 in
HEK293 cells, we found that USP28 colocalized with and stabi-
lized GFP-LSD1 in the nucleus (Figure 3F). Together, these data
indicate that USP28 interacts with LSD1 and this interaction isCmediated through the AO domain of LSD1 and N-terminal region
of USP28.
USP28 Stabilizes LSD1 through Deubiquitination
To test whether USP28 directly regulates protein stability of
LSD1, we coexpressed LSD1 with USP28 or vector control in
HEK293 cells and examined the degradation of LSD1. After
treatment with translational inhibitor cycloheximide to block
new protein synthesis, LSD1 degraded rapidly from the cells
transfected with a control vector (Figure 4A). However, LSD1
became stabilized in the presence of USP28, and this effect
can last up to 4 hr in the presence of cycloheximide. To test
whether endogenous LSD1 is also subjected to similar regulation
by USP28, we knocked down endogenous USP28 in HT29 cells
and found that endogenous LSD1 became unstable andell Reports 5, 224–236, October 17, 2013 ª2013 The Authors 227
Figure 3. USP28 Interacts with LSD1
(A) Flag-LSD1 was coexpressed with HA-USP28 in HEK293 cells. LSD1 and USP28 were immunoprecipitated with Flag or HA antibody, respectively, and the
associated USP28 and LSD1 were analyzed by western blotting using either HA or Flag antibody.
(B) Endogenous LSD1 and USP28 were immunoprecipitated fromBT549,MCF7, and HCT116 cells, and bound endogenous USP28 and LSD1were examined by
western blotting.
(C) Schematic diagram showing the structure of LSD1 and deletion constructs used (top panel). Flag-tagged full-length or deletion mutants of LSD1 were
coexpressedwith HA-USP28 in HEK293 cells. Extracts were immunoprecipitatedwith Flag or HA antibody, and bound USP28 or LSD1was examined bywestern
blotting using HA or Flag antibody (for input control, see Figure S3B).
(D) Lysate from HEK293 cells expressing HA-USP28 was mixed with WT or different deletion mutants of GST-LSD1. After pull-down by glutathione-agarose, the
associated USP28 was examined by western blotting using HA antibody.
(E) Schematic diagram showing the structure of USP28 and deletion constructs used (top panel). Flag-tagged full-length or deletion mutants of USP28 were
coexpressed Myc-LSD1 in HEK293 cells. Extracts were immunoprecipitated with Flag or Myc antibody, and bound LSD1 or USP28 was examined by western
blotting using either Myc or Flag antibody (for input control, see Figure S3C).
(F) GFP-LSD1 was coexpressed with Flag-USP28 in HEK293 cells. After fixation, the cellular location of LSD1 (green) and USP28 (red) was examined by
immunofluorescent staining (nuclei were stained with DAPI; blue). Arrowhead points to cell expressed GFP-LSD1 only. Scale bar, 25 mm.
See also Figure S3.degraded rapidly (Figure 4B). To further investigate whether this
USP28 effect is mediated through the deubiquitination of LSD1,
we coexpressed myc-LSD1 and HA-ubiquitin with either wild-
type (WT) or catalytic inactive (CI, C171A) mutant of USP28 in
HEK293 cells. After immunoprecipitating LSD1 from cells treated
with MG132, we found that LSD1 was heavily ubiquitinated (lane
2, Figure 4C). However, coexpression of WT-USP28, but not CI-
USP28, almost completely abolished LSD1 ubiquitination (lane 3
versus lane 4, Figure 4C). Conversely, LSD1 ubiquitination signif-
icantly increased in USP28 knockdown BT549 and MCF7 cells
after MG132 treatment (Figure 4D). These results indicate that
USP28 stabilizes LSD1 by removing its ubiquitination through
the deubiquitinase activity of USP28. To further extend this228 Cell Reports 5, 224–236, October 17, 2013 ª2013 The Authorscontention, we purifiedWT-USP28 andCI-USP28 and incubated
them separately with polyubiquitinated LSD1 in an in vitro deubi-
quitination assay as described by Dupont et al. (2009). We found
that WT-USP28, but not CI-USP28, specifically removed LSD1
ubiquitination (Figure 4E), indicating that USP28 directly deubi-
quitinated LSD1.
Knockdown of USP28 Directly Increases the Expression
of Differentiation Genes but Indirectly Suppresses the
Expression of Pluripotent Molecules
LSD1 is critical in controlling cellular differentiation and pluripo-
tency by regulating the expression of several differentiation
genes (such as p21Cif1/Waf1, HNF4, HoxA10, and FoxA2) and
Figure 4. USP28 Deubiquitinates LSD1
(A) Myc-LSD1 was coexpressed with vector or Flag-USP28 in HEK293 cells. After treating cells with cycloheximide (CHX) for indicated time intervals, expression
of LSD1 and USP28 was analyzed by western blotting (top panel) using Myc and Flag antibodies, respectively. The intensity of LSD1 expression for each time
point was quantified by densitometry and plotted (bottom panel). Experiment was repeated three times, and a representative experiment is presented. Exp,
exposure.
(B) HT29 cells were transfected with control or USP28 siRNA. After cells were treated with CHX, expression of endogenous LSD1 and USP28 was analyzed by
western blotting (top panel); the intensity of LSD1 expression for each time point was quantified by densitometry and plotted (bottom panel). Experiment was
repeated three times, and a representative experiment is presented.
(C) Myc-LSD1 and HA-ubiquitin were coexpressed with wild-type or catalytic inactive (CI, C171A) mutant of USP28 in HEK293 cells. After cells were treated with
or without 10 mM MG132 for 6 hr, LSD1 was immunoprecipitated and the polyubiquitination of LSD1 was detected by western blotting using HA antibody.
Immunoprecipitated LSD1 was blotted using Myc antibody.
(D) BT549 and MCF7 cells stably transfected with control or USP28 shRNA were treated with or without MG132 for 6 hr. Extracts were immunoprecipitated with
LSD1 antibody and the polyubiquitination of LSD1 was examined by western blotting using ubiquitin antibody.
(E) Ubiquitinated LSD1 was purified from MG132-treated HEK293 cells expressing Myc-LSD1 and then incubated with purified Flag-tagged wild-type USP28 or
CI-USP28 in a deubiquitination assay as described in Experimental Procedures. The polyubiquitinated state of LSD1 was examined by western blotting using HA
antibody. Immunopurified LSD1 and USP28 used in this assay were analyzed using Myc and Flag antibodies, respectively.pluripotent molecules (such as Sox2, Oct4, Nanog, and Bmi-1)
(Adamo et al., 2011). To investigate whether knockdown of
USP28 affects the expression of these LSD1 downstream tar-
gets, we established stable clones with knockdown of either
USP28 or LSD1 expression in breast cancer BT549 and MCF7
cells and achieved about 90% knockdown efficiency in these
cells. When measuring the mRNA level of these genes by real-
time PCR, we found the increase of several key lineage-specific
differentiation genes with USP28 knockdown (top panel, Fig-
ure 5A). In particular, USP28 knockdown led to an increased
expression of p21Cif1/Waf1 in both mRNA and protein level (Fig-
ures 5A and 5B). The upregulation of p21Cif1/Waf1 was not due
to the change of p53 because no difference in p53 expressionCwas found in cells with knockdown ofUSP28 or LSD1 (Figure 5B).
To strengthen the concept that USP28 affects the expression
of these differentiation genes through LSD1, we performed
chromatin immunoprecipitation (ChIP) to measure H3K4me2 at
the promoters of several of these target genes (p21Cif1/Waf1,
HNF4, HoxA10, and FoxA2). We found a great decrease of
LSD1 occupancy at the promoters of these targets in cells with
USP28 knockdown (Figures 5C and S4A). Consistent with this
observation, H3K4me2 was significantly increased at the
promoters of these genes. The reduced occupancy of LSD1 as
well as increased H3K4me2 at these target gene promoters
was specific due to the loss of LSD1, because cells with LSD1
knockdown had similar effects.ell Reports 5, 224–236, October 17, 2013 ª2013 The Authors 229
Figure 5. Knockdown of USP28 Alters the Expression of LSD1-targeted Genes
(A) Levels of mRNA of several differentiation and pluripotent genes from BT549 and MCF7 cells stably expressed control, USP28, or LSD1 shRNAs were
quantified by real-time RT-PCR. Values are normalized to actin (mean ± SD from three experiments in triplicate). *p value < 0.05; **p value < 0.01; and ***p value <
0.001 when the control group is compared with two individual clones expressing USP28 shRNAs and/or one clone expressing LSD1 shRNA.
(B) Cells above were analyzed for the expression USP28 and LSD1 as well as several pluripotent and differentiation molecules by western blotting.
(C) The association of LSD1 and the chromatinmethylationmarks (H3K4me2 andH3K9me2) at the LSD1-targeted gene promoters were analyzed by ChIP in cells
stably transfected control, USP28, or LSD1 shRNAs. Levels were determined by qPCR and expressed as percentage of input (mean ±SD from three experiments
in duplicate). Histone H3 and immunoglobulin G were served as a control in ChIP. *p value < 0.01 when the control group is compared with two individual clones
expressing USP28 shRNAs and one clone expressing LSD1 shRNA. NS, not significant.
See also Figure S4.We also observed the decrease of mRNA of several pluripo-
tent molecules (Sox2, Oct4, Nanog, and Bmi1) in two indepen-
dent clones with USP28 knockdown (bottom panel, Figure 5A).
Similar results were also found in cells with LSD1 knockdown.
These results indicate that the effect of USP28 is specifically
mediated through the downregulation of the protein level of
LSD1 in these cells, because the mRNA level of LSD1 remained
intact in two individual clones with USP28 knockdown. The
mRNA downregulation of Sox2 and Oct4 correlated with the
decreased occupancy of RNA polymerase II at their promoters
in BT549 and MCF7 cells with knockdown expression of either
USP28 or LSD1 (Figure S4B). Downregulation of Sox2 and
Oct4 were further validated by western blot analysis (Figure 5B).
However, we could not detect an association of LSD1 at the
Sox2 and Oct4 promoters by ChIP (Figure S4B), suggesting
that LSD1 indirectly regulates the expression of Sox2 and Oct4
in these cells. In addition, knockdown of USP28 or LSD1 did
not significantly alter the level of H3K9me2 onmost of these pro-230 Cell Reports 5, 224–236, October 17, 2013 ª2013 The Authorsmoters in both cell lines (Figures 5C and S4A); this is consistent
with the observation that USP28 knockdown did not impair the
global levels of H3K9me2 (Figure S1B). Together, these data
indicate that USP28 regulates the expression of differentiation
genes directly and pluripotency activators indirectly through
LSD1 stabilization.
Knockdown of USP28 Induces Differentiation and
Suppresses Self-Renewal in Cancer Stem Cells Derived
from MMTV-Wnt1 Mice
Phenotypic and functional heterogeneity is a defining feature of
leukemia and seen in many solid tumors. It is believed that only
a subset of cancer stem cells (CSCs) is responsible for the het-
erogeneity and efficient propagation of bulky tumors, because
CSCs exhibit the ability for unlimited self-renewal and the capac-
ity for differentiation (Nguyen et al., 2012). Because LSD1 is crit-
ical in controlling the expression of differentiation genes directly
and pluripotency activators indirectly, we investigated whether
Figure 6. USP28 Is Required to Maintain CSC-like Features in Breast Cancer Cells via LSD1
(A) Phase-contrast micrograph of MMTV-Wnt1 cells stably transfected with control vector, USP28 shRNA, or in a USP28 knockdown clone with LSD1-rescued
expression. Scale bar, 100 mm.
(B) Tumorsphere formation is examined in cells above. Representative images of tumorsphere were shown. Scale bar, 100 mm.
(C) Quantification of tumorspheres from cells in (B) was plotted and shown.
(D) CD49flow/CD24high population in cells above was analyzed by FACS.
(E) Representative images of the 3D structures formed by cells above in Matrigel (top panel) were presented. Cellular structures were stained for CK14 and
E-cadherin (bottom panel; nuclei were stained with DAPI). Scale bar, 20 mm.
(F) Data presented are a quantification of the numbers of solid organoid and acini-forming structures from (E).
(G) mRNA levels of several basal and luminal genes from cells above were quantified by real-time RT-PCR. Values were normalized to 18S.
(H) Lysates from cells above were analyzed by western blotting.
In (C), (D), (F), and (G), data presented are representative of three experiments performed in duplicates as themean ±SD. *p value < 0.05; **p value < 0.01; and ***p
value < 0.001 when the control group or rescued group was compared with two individual clones expressing USP28 shRNAs.
See also Figure S5.the USP28-LSD1 axis was involved in the regulation of CSCs
self-renewal and differentiation. To this end, we selected cells
isolated fromMMTV-Wnt1 tumormodel, in whichWnt1 preferen-
tially targets mammary stem cells and leads to a profound
expansion of mammary stem cells in tumors (Liu et al., 2004).
Consistent with the our contention that the USP28-LSD1 axis
is critical in regulating CSC-like properties, expression of
USP28 and LSD1 was significantly higher in cells isolated from
MMTV-Wnt1 tumors than those from normal mammary glandsCor tumors from MMTV-HER2 mice (Figure 2B). Cells isolated
from MMTV-Wnt1 tumor grew as sphere-cluster structures in
monolayer; USP28 knockdown conferred morphological
changes as the cells became disassociated and scattered, a
phenomenon associated with cellular differentiation (Figure 6A)
(Guo et al., 2012; Jeselsohn et al., 2010). In addition, USP28
knockdown resulted in fewer and smaller tumorspheres than
parental cells under nonadherent condition, suggesting that
USP28 knockdown impairs the self-renewal and enhancesell Reports 5, 224–236, October 17, 2013 ª2013 The Authors 231
differentiation of CSCs from MMTV-Wnt1 tumors (Figures 6B
and 6C). Consistent with this finding, the population of non-
CSCs, thosewith aCD49flow/CD24high expression profile, greatly
increased in USP28 knockdown MMTV-Wnt1 CSCs (Figures 6D
and S5).
We further examined colony formation in Matrigel to assess
the differentiation event associated with USP28 knockdown.
Colonies from parental MMTV-Wnt1 CSCs grew as a large solid
organoid with apparent expression of CK14 (basal marker) and
lack of expression of E-cadherin (luminal marker). However,
USP28 knockdown not only reduced the size of colonies but
also shifted these colonies from solid organoid to a more
acinar-like structure, accompanied by a reduced CK14 expres-
sion and increased E-cadherin expression (Figures 6E and 6F).
Real-time PCR further validated the reduced expression of basal
markers (CK14 and smooth muscle actin SMA) and increased
expression of luminal molecules (E-cadherin and ELF5) in
USP28 knockdown colonies (Figure 6G). Notably, LSD1-rescued
expression reversed morphological changes, restored tumor-
sphere formation, reduced the non-CSC population, and re-
turned expression of basal markers in USP28 knockdown cells
(Figures 6A–6G). Consistent with these findings, USP28 knock-
down reduced the expression of Sox2 and Oct4, whereas
LSD1-rescued expression restored their expressions (Figure 6H).
Together, our data indicate that the USP28-LSD1 axis is required
for regulating the self-renewal and differentiation properties of
CSCs derived from MMTV-Wnt1 tumors.
Knockdown of USP28 Inhibits CSC-like Traits In Vitro
and Suppresses Tumorigenicity In Vivo
To further examine the USP28-LSD1 axis in regulating CSC-like
properties in human breast cancer, we measured tumorsphere
formation in BT549 and MCF7 cells with knockdown of USP28.
We found that USP28 knockdown reduced the number and
size of primary tumorspheres in BT549 and MCF7 cells (Figures
7A and 7B). Knockdown of USP28 also reduced the number and
size of secondary tumorspheres (Figure 7B). This function of
USP28 is likely mediated through the regulation of LSD1,
because knockdown of LSD1 also inhibited the number and
size of tumorspheres to a similar extent in these two cell lines
(Figures 7A and 7B). Consistent with this idea, USP28-mediated
inhibition on tumorsphere formation was largely restored by
LSD1-rescued expression (vector expressing LSD1-IRES-GFP)
in these cells (Figures 7A and 7B). As human breast CSCs are
enriched in CD44high/CD24low population (Fillmore and Kuper-
wasser, 2007), we measured the CD44high/CD24low population
in BT549 and MCF7 cells with knockdown of USP28 or LSD1.
We found that USP28 knockdown reduced CD44high/CD24low
population in both BT549 and MCF7 cells (Figures 7C and
S6A); similar observations were noted with LSD1 knockdown
in these two cell lines. Again, the reduction of CSC population
in USP28 knockdown clone could be restored by LSD1-rescued
expression. To further confirm this, we also used EpCAM+/
CD49fhigh/CD24low as cell-surface markers in sorting cells that
are known to be enriched with CSCs in breast cancer (Plaks
et al., 2013; Stingl et al., 2006). As expected, similar results
were obtained (Figure S6B). The difference of CSC populations
among vector-control cells, USP28 knockdown cells, and232 Cell Reports 5, 224–236, October 17, 2013 ª2013 The AuthorsLSD1-rescued cells is unlikely to be due to the variable gating
in FACS analysis as same gating was used in each assay (Fig-
ure S6C). In line with the critical role of the USP28-LSD1 axis in
regulating CSC-like characteristics, USP28 knockdown reduced
the expression of Sox2 and Oct4 and LSD1-rescued expression
restored their downregulations (Figure 7D).
To further extend our findings in vivo, we implanted the
following cells in the mammary fat pad of female SCID mice:
(1) vector control MCF7 cells; (2) USP28- or LSD1 knockdown
MCF7 cells; and (3) LSD1-rescued expression in USP28 knock-
down MCF7 cells. Strikingly, knockdown of USP28 or LSD1
significantly inhibited tumor growth in vivo (Figure 7E). The sizes
of tumors from these mice were significantly smaller than that
from vector control mice. We also found that the levels of Sox2
and Oct4 were greatly reduced in tumors with knockdown of
USP28 or LSD1 (Figures S6D and S6E). Consistent with results
obtained in cell culture, LSD1-rescued expression largely
restored tumor growth and tumor formation (Figure 7E). In addi-
tion, expression of Sox2 and Oct4 was also restored in these
tumors (Figures S6D and S6E). Furthermore, the proliferation in-
dex Ki67, which was significantly reduced in tumors from USP28
and LSD1 knockdown cells, increased in tumors derived from
LSD1-rescued cells (Figure S6E). Together, these results indi-
cate that USP28 is critical in controlling CSC-like properties
and tumorigenicity through LSD1.
DISCUSSION
In this study, we found that USP28 interacted with and stabilized
LSD1 from ubiquitination. We showed that USP28 was overex-
pressed in breast cancer cells and conferred them with CSC-
like features that are mediated through LSD1 stabilization. Our
study has revealed several insights into the ubiquitination and
chromatin regulation in breast cancer. First, our data indicate
that USP28 is a specific DUB for LSD1, because knockdown
of USP28 reduced LSD1 stability, whereas overexpression of
USP28 stabilized LSD1. This event required the catalytic activity
of USP28 because a catalytically inactive mutant could not sta-
bilize LSD1. In addition, USP25, the most related member of this
subtype, could not stabilize LSD1, indicating the specificity of
USP28 for LSD1. We further mapped and identified the AO
domain of LSD1 and the N-terminal region of USP28 as required
for their mutual interactions. Although we did not notice any
correlation between the mRNA of USP28 and LSD1 in several
microarray data sets and various tumor cell lines, we did find a
significant correlation between USP28 and LSD1 in protein level
on cancer cell lines and tumors from mouse models and human
breast cancer specimens, confirming that the regulation of LSD1
by USP28 is a posttranslational event. In agreement with this
notion, knockdown of USP28 reduced the protein level and func-
tional activity of LSD1, but these could be rescued by exogenous
LSD1 expression (Figure 7F).
The limited numbers of DUBs in the human genome suggest
that each DUB may have several substrates. Indeed, USP28
has been shown to deubiquitinate c-Myc and p53BP1 (Popov
et al., 2007; Zhang et al., 2006). Different from the interaction
of USP28 with LSD1, USP28-mediated p53BP1 stabilization
only occurs after DNA damage, and no effect is found in the
Figure 7. Knockdown of USP28 Inhibits CSC-like Traits In Vitro and Suppresses Tumorigenicity In Vivo
(A) Tumorsphere formation was examined in BT549 andMCF7 cells stably expressing control, USP28, and LSD1 shRNAs and in a USP28 knockdown clone with
LSD1-rescued expression (LSD1-IRES-GFP). Representative images of primary tumorspheres from these cells were shown. Scale bar, 100 mm.
(B) Quantification of primary and secondary tumorsphere from above experiments were plotted and shown (mean ± SD from three independent experiments). *p
value < 0.01 when control or rescued group was compared with two groups with USP28 shRNAs and one group with LSD1 shRNA.
(C) CD44high/CD24low population in cells above was examined by FACS analysis. Quantification of CD44high/CD24low population was presented (mean ± SD from
three independent experiments). *p value < 0.01 when control or rescued group was compared with two groups with USP28 shRNAs and one group with LSD1
shRNA.
(D) Lysate from cells above were analyzed by western blotting.
(E) MCF7 cells stably transfected with control, USP28, or LSD1 shRNAs or a USP28 knockdown cells with LSD1-rescued expression were injected intomammary
fat pad of female SCID mice. Xenograft tumor size was measured twice a week. Data points represent the mean ± SD of six mice per group. The mean of tumor
growth was presented in the top panel, and tumors from these mice were shown in the middle panel. The mean of tumor weight was presented in the bottom
panel. Statistical analysis was performed using Student’s t test. **p < 0.001; comparisons include group from vector control cells or USP28 knockdown cells with
LSD1 expression compared with two groups with USP28 shRNAs and one group with LSD1 shRNA.
(F) A proposed model to illustrate USP28 induces LSD1 stabilization through a deubiquitination event and thus results in the maintenance of pluripotency by
blocking cellular differentiation via suppressing H3K4me2 on LSD1-targeted differentiation gene promoters.
See also Figure S6.absence of DNA damage, suggesting that the interaction
between USP28 with p53BP1 is regulated by DNA damaging.
On the other hand, USP28 does not directly interact with Myc
but rather associates with an E3 ligase of Myc, Fbw7, to coun-
teract Fbw7-mediated Myc ubiquitination. Knockdown of
USP28 shifts the balance toward Fbw7-mediated ubiquitination.
In our study, we found that knockdown of Myc did not affect theCbinding between USP28 and LSD1 (Figure S6F). In addition,
LSD1-rescued expression restored, to large extent, the func-
tions mediated by USP28 knockdown. Although our results indi-
cate that LSD1 is a major target of USP28 in breast cancer, it
does not rule out the possibility that USP28 promotes CSC-like
traits through both LSD1 stabilization and inhibition of Myc
degradation.ell Reports 5, 224–236, October 17, 2013 ª2013 The Authors 233
Second, our study indicates that USP28 provides an addi-
tional layer of control on CSC-like properties through LSD1 sta-
bilization. In ESCs, the promoters of developmental regulators
are simultaneously poised with bivalent marks, H3K4me3 and
H3K27me3, representing both active and repressive modifica-
tions that are controlled by trithorax and polycomb (PcG) com-
plexes, respectively. During differentiation, pluripotent genes
lose active (H3K4me3) modification while maintaining the
repressor mark (H3K27me3), whereas the lineage-specific
developmental genes, silent in pluripotent ESCs, retain the acti-
vation modification and lose the repressive mark for expression
upon differentiation. Recent studies indicate that LSD1 oc-
cupies the promoter of a subset of developmental genes con-
taining bivalent domains (Adamo et al., 2011). High levels of
LSD1 are required to tightly control the level of H3K4 methyl-
ation at the regulatory regions of developmental genes for the
maintenance of pluripotency and suppression of differentiation.
Consistent with this notion, knockdown of USP28 greatly
enhanced H3K4me2 at the promoter region of p21Cif1/Waf1,
HNF4, HoxA10, and FoxA2 and upregulated the expression of
these differentiation genes directly. Although we noticed
reduced occupancy of RNA polymerase II at the promoters of
Sox2 and Oct4 and a corresponding downregulation of mRNA
and protein of these molecules in USP28 knockdown cells, we
could not detect an association of LSD1 at the Sox2 and Oct4
promoters in ChIP experiments. Our results suggest that
LSD1 does not directly regulate the expression of Sox2 and
Oct4. Recent studies also show that LSD1 knockdown signifi-
cantly reduces the expression of Sox2 and Oct4 and that
LSD1 does not directly control the expression of these genes
during cellular differentiation (Adamo et al., 2011; Wang et al.,
2011). Although the detailed mechanism remains elusive, it
has been proposed that the differentiation genes that are
directly controlled by LSD1 can indirectly suppress the expres-
sion of Sox2 and Oct4. Future thorough investigations using
various cellular differentiation systems are required to provide
a comprehensive understanding regarding this intricate regula-
tion by LSD1.
In agreement with these molecular changes, the USP28-LSD1
axis is critical in controlling the differentiation and self-renewal of
breast CSCs frommouse model and human cancer. Intriguingly,
increased USP28 expression positively correlated with LSD1
upregulation in tumors from MMTV-Wnt1 mice but not from
normal mouse mammary gland or tumors from MMTV-HER2
mice. This observation is compatible with the notion that Wnt
signaling is critical in self-renewal and the maintenance of
cellular pluripotency. USP28 knockdown suppressed the self-
renewal abilities and enhanced differentiation capacities in
CSCs from MMTV-Wnt1 tumors. USP28 knockdown also sup-
pressed the CSC-like traits in human breast cancer cell lines
in vitro and inhibited tumorigenicity in vivo. LSD1-rescued
expression largely restored these defects. These data provide
substantial support to our contention that USP28 is critical for
controlling CSC-like properties via LSD1 stabilization in breast
cancer (Figure 7F). Similar to our finding, Williams et al. has
shown that USP1 preserved a mesenchymal stem cell program
through deubiquitination of ID protein (Williams et al., 2011). In
addition, USP1 is overexpressed in gastric cancer and correlates234 Cell Reports 5, 224–236, October 17, 2013 ª2013 The Authorswith transformation and aggressiveness of this disease (Luise
et al., 2011). Thus, our study, and those of others, point to the
critical function of USP in controlling CSC-like characteristics
through the regulation of several key transcriptional molecules.
Third, our study indicates that USP28 is a druggable target for
inhibiting breast CSC-like characteristics (Figure 7F). CSCs are a
rare subpopulation that is intrinsically resistant to therapy and
allows tumor regrowth and metastasis. Targeting this subpopu-
lation of breast CSCs, as well as the other tumor cells, presents a
winning approach to prevent tumor relapse. Consistent with the
critical role of LSD1 in regulating CSC-like properties, inhibition
of LSD1 using Parnate induced differentiation and expression
retinoic acid receptor in acute myeloid leukemia (AML), and
thus sensitized AML cells to growth suppression by all-trans-ret-
inoic acid (Schenk et al., 2012). In addition, inhibition of LSD1
using Parnate suppresses colon cancer and neuroblastoma
growth in vitro and in xenograft mouse models (Huang et al.,
2007, 2009; Schulte et al., 2009). These preclinical studies are
in line with the observation that LSD1 is overexpressed in multi-
ple types of cancer and has tumor-promoting effects. However,
commonly used LSD1 inhibitors, such as Parnate, were originally
developed to inhibit Monoamine oxidase A and B for the treat-
ment of Parkinson’s disease and other neurodegenerative disor-
ders. They are nonselective amine oxidase inhibitors, and they
induce substantial toxicity in vitro and in vivo. In this study, we
found that USP28was themajor factor responsible for LSD1 sta-
bilization in cancer cell lines and tumor samples, and that knock-
down of USP28 decreased the level of LSD1 and suppressed
CSC-like properties in vitro and tumorigenicity in vivo. Notably,
the copy number gained of USP28 was identified as one of the
six genes that presented in both primary tumor and metastatic
lesions from patients with invasive lobular breast cancer on a
genome-wide sequencing study (Shah et al., 2009). In addition,
expression of USP28 was strongly elevated in human breast
and colon carcinoma (Popov et al., 2007). Together, our study
and those of others indicate that USP28 represents a key modu-
lator in facilitating tumor development and progression. Thera-
peutics targeting USP28 provides an excellent alternative
approach for overcoming the nonspecific side effects of LSD1
inhibitors in treating patients with breast cancer.
EXPERIMENTAL PROCEDURES
Antibodies and Plasmids
Detailed information is provided in the Extended Experimental Procedures.
siRNA Library Screening
The human deubiquitinating enzyme siGENOME RTF Library was purchased
from Dharmacon. The screen was performed according to manufacturer’s
instructions. Briefly, HEK293 cells were added to the rehydrated Dharmacon
RTF siRNA library plates (96-well plates). Two days later, cell lysates were
extracted and the expression of endogenous LSD1 was examined by western
blotting.
Matrigel Organoid Culture
MMTV-Wnt1 tumor cells were cultured with DMEM/F12 medium supple-
mented with 5%Matrigel, 5 ng/ml EGF, 5% horse serum, 0.5 mg/ml hydrocor-
tisone, 10 mg/ml insulin, and 100 ng/ml Cholera toxin. Cells were seeded at
25,000/well in 24-well plate. The number of organoid and acinar structures
was counted 5–7 days after seeding by visual inspection.
In Vivo Ubiquitination Assay
HEK293 cells were transfected with HA-ubiquitin, Myc-LSD1, and Flag-USP
plasmids as indicated. The cells were treated for 6 hr with 10 mM MG132 at
42 hr posttransfection and then lysed. The samples were immunoprecipitated
using anti-Myc agarose (Sigma).In Vitro Deubiquitination Assay
The in vitro deubiquitination was performed as described (Dupont et al., 2009).
Briefly, HA-ubiquitin and Myc-LSD1 were coexpressed in HEK293 cells. At
42 hr posttransfection, cells were treated with 10 mMMG132 for 6 hr to enrich
the ubiquitinated form of LSD1. Myc-tagged ubiquitinated LSD1 was purified
by immunoprecipitation with anti-Myc-agarose bead (Sigma) followed by
elution with Myc peptide. In a parallel experiment, Flag-USP28 (wild-type
and catalytic-inactive mutant) was expressed in HEK293 cells for 48 hr.
Flag-USP28 was purified by immunoprecipitation with anti-Flag-agarose
bead (Sigma) followed by elution with Flag peptide. For in vitro deubiquitination
assay, purified ubiquitinated Myc-LSD1 was incubated with purified Flag-
USP28 in a deubiquitination reaction buffer (50 mM HEPES [pH 7.5],
100 mM NaCl, 5% glycerol, 5 mM MgCL2, 1 mM ATP, and 1 mM DTT) at
30C as described by Dupont et al. (2009). The reaction mixture was dissolved
in SDS-PAGE buffer and analyzed by western blotting.
Other methods are included in the Extended Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2013.08.030.ACKNOWLEDGMENTS
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